



Tecentriq® (atezolizumab) – New Indication

- On October 18, 2016, [Genentech announced](#) the FDA approval of [Tecentriq \(atezolizumab\)](#) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.
 - Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq.
- Tecentriq is also approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- According to the American Cancer Society, it is estimated that more than 224,000 Americans will be diagnosed with lung cancer in 2016, and NSCLC accounts for up to 85% of all lung cancers. It is estimated that approximately 60% of lung cancer diagnoses in the U.S. are made when the disease is in the most advanced stages.
- Tecentriq's new indication was evaluated in two clinical trials (OAK and POPLAR) comprising of 1,512 patients with metastatic NSCLC who progressed during or following a platinum-containing regimen. Patients were randomized to treatment with Tecentriq or [docetaxel](#). The primary outcome in both studies was overall survival (OS).
 - OAK demonstrated a greater OS with Tecentriq vs. docetaxel (median OS: 13.8 vs. 9.6 months; hazard ratio = 0.74, 95% CI: 0.63, 0.87; p = 0.0004). The median follow up was 21 months.
 - POPLAR demonstrated a greater OS with Tecentriq vs. docetaxel (median OS: 12.6 vs. 9.7 months; hazard ratio = 0.69, 95% CI: 0.52, 0.92). The median follow up was 22 months.
- The most common adverse reactions (≥ 20%) with Tecentriq use in patients with metastatic NSCLC were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation.
- Similar to the recommended dose of Tecentriq for urothelial carcinoma, the dose for metastatic NSCLC is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.